Osmind

02/05/2026

One clinician saw their Spravato reimbursement drop $90 overnight in January. The culprit? A billing code change nobody warned them about.

CMS replaced S0013 with J0013 in 2026. Same drug. Same unit. New code. But the rollout has been messy:

→ Payer systems weren't updated in time
→ Prior authorizations are being handled inconsistently
→ Some practices are already seeing claim rejections

The scariest part for buy-and-bill practices? If a PA isn't valid, you could be out over $1,000 for medication you've already purchased and administered.

We pulled together what clinicians in the Osmind community are seeing: payer-specific guidance, PA reauthorization tips, and a documentation checklist so you're not caught off guard.

Consider it a living document. We're learning alongside you.

CMS replaced S0013 with the new Spravato J code (J0013) in 2026, but payer rollouts have been inconsistent. Learn which prior authorizations need to be redone and how to protect your practice from claim denials.

02/03/2026

Just wrapped ASKP3 and feeling energized. Some highlights from the conference:

• The conversation has shifted. Clinicians aren't just talking about ketamine anymore—they're asking how to add TMS, Spravato, and accept insurance to build sustainable, long-term practices. The next evolution of interventional psychiatry is here.

• Compliance questions are changing. Less "can I do this?" and more "how do I do this right?" Clinicians want to offer innovative treatments confidently—and they're looking for partners who understand the regulatory landscape.

•Osmind Scientific Advisor L. Alison McInnes MD, MS. presented real-world data on ketamine for PTSD from 1,340 patients across our network.

Thank you to everyone who stopped by, shared your stories, and reminded us why we do this work. The future of interventional treatment is bright, and it's being built by clinicians like you.

01/31/2026

The cost of treatment resistance: Each failed antidepressant trial actively worsens patient outcomes.

Join us February 19, 2026 for a deep dive into the clinical evidence behind VNS Therapy™—featuring findings from the RECOVER trial, the largest randomized controlled study of VNS Therapy for difficult-to-treat depression.

What you'll learn:
➡️ Why treatment outcomes worsen with each failed trial (STAR*D insights)
➡️ What is VNS Therapy and how does it work?
➡️ Key findings from the RECOVER trial: the largest randomized controlled study of VNS Therapy
➡️ Which patients may benefit most from VNS Therapy based on treatment history

Expert speakers: Hamish McAllister-Williams, MD | Northern Centre for Mood Disorders, Newcastle University & Dr. William Sauvé, MD | Chief Medical Officer, Osmind

Can't attend live? Register to receive the recording.
[REGISTRATION LINK] https://osmind-org.zoom.us/webinar/register/WN_INZArKsaR-yIeQfZMQLfhg

Selected by Osmind | Sponsored by LivaNova, PLC
More information about VNS Therapy for Difficult-to-treat Depression (DTD) is available at https://www.livanova.com/depression/en-us

The VNS Therapy™ System is indicated for the adjunctive long-term treatment of chronic or recurrent depression for patients 18 years of age or older who are experiencing a major depressive episode and have not had an adequate response to four or more adequate antidepressant treatments.

Important safety information is available at https://www.livanova.com/depression/en-us/hcp-safety-information

DEP-2500191

01/22/2026

Proud to sponsor American Society of Ketamine Physicians, Psychotherapists and Practitioners (ASKP3) every year since its inception.

Interventions like ketamine are changing lives, and this community is leading the charge.

This year, Osmind Scientific Advisor L. Alison McInnes MD, MS. takes the main stage to present real-world data on ketamine for PTSD from 1,340 patients across our network.

See you in Austin!

01/21/2026

Sleep is a single-player experience. You have no idea how the person next to you sleeps or whether your own fatigue is normal. So sleep disorders go unrecognized and get labeled TRD, anxiety, ADHD.

The stereotype of sleep apnea is an overweight 65-year-old man snoring on the couch. It's now showing up earlier, in different presentations.

Brittany Albright MD, MPH, DABOM refers almost every TRD patient for sleep testing. Most come back positive. Some longstanding ADHD cases—no childhood history, stimulants not quite working. "Lo and behold, they have sleep apnea. They get treated and I've been able to remove the ADHD diagnosis and deprescribe stimulants.”

The 2-3am wake-up you think is anxiety? It could be the airway collapsing during the third REM cycle where muscle tone is lowest. Women get missed constantly; their apnea often clusters in REM sleep, so overall scores look normal even when they're not.

Only 150 sleep fellows graduate annually. Wait times hit 9–12 months. Patients get tested, come back negative, return to psychiatry with a Seroquel recommendation. The symptom gets treated, but the cause doesn't.

So what’s a psychiatrist to do?

🎧 Listen/read as Drs. Avinesh Bhar, MD MBA, William Sauvé, MD, and Brittany Albright MD, MPH, DABOM discuss why sleep disorders hide behind psychiatric diagnoses, and how to catch what's being missed.

Sleep apnea and depression are more connected than most clinicians realize—and standard testing often misses it. Dr. Avinesh Bhar breaks down the link and what psychiatrists can do about it.

01/16/2026

Just back from ACNP 2025 in Paradise Island, Bahamas. A few research highlights that stood out:

Obesity-depression subtypes are gaining traction. Dr. Roger McIntyre presented his classification system showing that Class 3 patients—those with insulin resistance, inflammation, and visceral adiposity—may represent a distinct subtype requiring targeted treatment approaches.

His work continues to earn well-deserved recognition from the psychiatric research community.

We presented our own research on BMI and ketamine therapy outcomes. Analyzing data from over 16,000 patients on the Osmind platform, we found BMI relates differently to symptom trajectories depending on the condition:

Depression: U-shaped relationship—both low and high BMI linked to higher symptom severity, but higher BMI predicted slightly greater improvement across infusions.

Anxiety & PTSD: Higher BMI associated with lower baseline symptoms, though no effect on rate of improvement.

The takeaway: metabolic health indicators like BMI may help clinicians contextualize symptom burden and set expectations for ketamine therapy response.

Trauma + inflammation = ketamine responders? Emerging data suggests MDD patients with comorbid trauma history and elevated inflammation markers may respond particularly well to ketamine and esketamine. This could help clinicians identify who's most likely to benefit.

Microdosing update: still underwhelming. Sessions reinforced what prior research has shown: microdosing psychedelics hasn't demonstrated meaningful clinical efficacy. Therapeutic signal remains with full doses in supported settings.

Grateful to the American College of Neuropsychopharmacology , Dr. Roger McIntyre, Dr. Rob Berman, and the Osmind team inlcuding Jimmy Qian, Dr. Emily Shih, William Sauvé, MD, L. Alison McInnes MD, MS, Dr. Jamie L., PhD MPH

01/12/2026

VNS therapy exists because a scientist went to Lamaze class with his pregnant wife...

In the 1980s, neuroscientist Jake Zabara was studying the vagus nerve in dogs when he started attending childbirth preparation classes.

Sitting there learning breathing techniques, he asked a question most people wouldn't think to ask: How does controlled breathing actually reduce the pain of contractions?

His hypothesis: the vagus nerve, running from the diaphragm to the brain, was the pathway.

He went back to his lab, isolated the vagus nerve in dogs, and started stimulating it directly. The rest became the foundation for a treatment that now helps patients with severe, treatment-resistant depression.

Another example of serendipity in psychiatry. The biggest breakthroughs often come from paying attention to the small, strange observations.

Learn more about Vagus Nerve Stimulation and keep your finger on the pulse of the future of psychiatry. Listen to the full episode on Psychiatry Tomorrow.
This episode features William Sauvé, MD, Lucian Manu, M.D., Carlene MacMillan, MD, FCTMSS,DFAACAP

Search your podcast player or find the link below.

12/12/2025

Happy 4th Osmoversary to Michael Bartimer! 🎉**

Four years ago, Michael cold-emailed us after spotting our YC announcement, eager to join an early-stage mental health startup and do whatever it took to make an impact. That scrappy energy has defined his entire Osmind journey.

From his early days in Customer Success to becoming our Sr. RevOps Manager, Michael has been the ultimate connector—building the automations, tooling, and AI-powered workflows that keep our systems running smoothly and finding signal amidst noise. He has a knack for finding signal in the noise and the fulcrum points that make everything easier.

Recently, Michael was recognized as a top RevOps leader and featured in Times Square, a well-deserved spotlight for someone who's been quietly powering Osmind behind the scenes since nearly day one.

Here's to four years of hustle, innovation, and being an OG Osmo. Cheers, Michael! 🥳

12/10/2025

Here's what you missed this month in the Osmind Psychiatry Collective, a community of 2,500+ innovative practitioners advancing interventional psychiatry through case discussions, treatment protocols, and peer consultation.

📡 Medicare telehealth regulation changes (live event): Members discussed upcoming virtual practice requirements and billing implications during a focused session on regulatory challenges. Key insights on avoiding inadvertent Medicare fraud with clear compliance guidance.

💊 GLP-1 medications in psychiatry (Clinical Coffee Chat): We explored using GLP-1s for alcohol use disorder and other mental health condition, and foundational lifestyle interventions.

🧠 Complex case management strategies (live event with Dr. William Sauve): Members shared clinical perspectives on treating challenging psychiatric cases, highlighting creative treatment approaches and maintaining therapeutic alliances during patient crises.

📅 November wrap-up & December planning: November’s theme was all about practice management. Members are planning for mental health during the holidays and goals for the upcoming year.

Ready to join your peers inside the Psychiatry Collective? Free with the link below 👇

12/03/2025

When Dr. Martha Koo interviews candidates for her interventional psychiatry practice, she doesn't ask about their resume. She puts them back-to-back with a stranger and hands one of them a picture.

"Describe this so they can draw it. You can't see what they're drawing."
"There's a difference between 'draw a circle on the page' versus 'can you draw a circle, maybe the size of a quarter, in the exact center middle of the page,'" she explains.

She's watching for precision. Patience when the other person struggles. Whether they blame or adjust.

Dr. Koo has been running TMS practices for 15 years. Her first technician? Now runs recruiting for her entire organization.

She stopped filtering for credentials a long time ago.

"There is no standardized TMS certification, no standardized esketamine certification," says William Sauvé, MD, who co-founded practices that became Greenbrook TMS.

"You're going to have to train those people yourself."

We polled the Osmind Psychiatry Collective: what matters most in a new hire? Empathy came in first. Technical skill came in dead last.

"Nobody comes to this clinic because they're feeling great and everything's going perfect," Dr. Sauvé tells his staff. "You need people who can resolve things and not get upset when things get a little chaotic."

You can teach someone to run a TMS machine. You can't teach them to stay calm when a patient with treatment-resistant depression gets frustrated at session 15.

Drs. Koo and Sauvé share their full hiring framework, including interview exercises, scoring rubrics, onboarding checklists. We turned it into a guide:

Two interventional psychiatrists share their complete hiring playbook, from who to hire first, to interview exercises that reveal fit. Downloadable template included.

12/02/2025

Osmind leadership, including Lucia Huang, Jimmy Qian, and William Sauve, presented a webinar as part of Cantor Fitzgerald's biotechnology webinar series "Let's Do Some Psychedelics!" led by Josh Schimmer.

With rapid advances in psychedelics research and drug development, the care delivery ecosystem must prepare to offer these new treatment modalities upon FDA approval.

Equities coverage has not traditionally focused as much on a deep understanding of clinic infrastructure, so we were pleased to provide these insights to Cantor's clients as they analyze the dynamic interventional psychiatry sector. Thanks to Josh Schimmer and the Cantor Fitzgerald team for the opportunity.

11/24/2025

As psychedelic medicines continue to move closer to FDA approval, the field needs to start laying the groundwork for commercial launch, patient access, and clinic support.

Our co-founder Jimmy Qian shared perspectives at CNS Summit earlier this month on what we're learning across the ecosystem: working with 800+ interventional psychiatry practices, conducting the first real-world evidence study from legal Oregon psilocybin services, collaborating with biopharma on launch preparation and commercial development, and engaging with government stakeholders on infrastructure needs.

The field is evolving fast. Thanks to CNS Summit for bringing together the researchers, clinicians, and industry leaders pushing this work forward.